In the original languageTranslation into English
IMMUNOHISTOCHEMICAL CHARACTERISTICS AND THEIR EFFECT ON THE CLINICAL COURSE AND PROGNOSIS OF DIFFUSED B-LARGE CELL LYMPHOMA WITH EXTRANODAL LESIONS
Authors
Atakhanova N.E., Kobilov O.R.
Rubric:Clinical Medicine
451
2
Share
451
2
Annotation
The study included 81 patients with diffuse large B-cell lymphoma with extranodal lesions, who were under examination and treatment from 2015 to 2021 inclusive. We observed 81 patients with 10 types of DLBCL. The most frequently identified primary mediastinal form (19.8%), intravascular form (18.5%), lymphomatoid granulomatosis, which in the usual histological examination is confused with Hodgkin's lymphoma (16%) and with the predominance of T - cells. Less common were plasmablastic, ALC positive, with IRF4 rearrangement, and primary DLBCL of serous cavities.
Keywords
IHC; diffuse B-large cell lymphoma; extranodal lesion
Authors
Atakhanova N.E., Kobilov O.R.
Rubric:Clinical Medicine
451
2
Share
451
2
References:
- Phan J.; Mazloom A.; Medeiros L.J. et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol. 2019;28(27):4170-6.
- Kridel R.; Dietrich P.Y. Prevention of CNS relapse in diffuse large B- cell lymphoma. Lancet Oncol 2017;12:1258–1266.
- Wilson W.H; Dunleavy K.; Pittaluga S. et al. Phase II study of dose- adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol. 2018;26(16):2717-24
- Coiffier B.; Lepage E.; Briere J. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2020;346:235–242
- Peyrade F.; Jardin F.; Thieblemont C. et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2019;12:460– 468
- Moccia A.A.; Schaff K.; Hoskins P. et al. R-CHOP with Etoposide Substituted for Doxorubicin (R-CEOP): Excellent Outcome in Diffuse Large B Cell Lymphoma for Patients with a Contraindication to Anthracyclines. Blood (ASH Annual Meeting Abstracts) 2019;114:Abstract 408
- Philip T.; Guglielmi C.; Hagenbeek A.; et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin"s lymphoma. N Engl J Med. 2020;333(23):1540-5
- Zelenetz A.D.; Hamlin P.; Kewalramani T. et al. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non- Hodgkin"s lymphoma. Ann Oncol. 2018;14 Suppl 1:i5-10
Other articles of the issue
